The goal of ProVivoX is to use characteristics of the tumor against itself: more specifically, we want to identify if the patient would benefit from chemotherapy by dosing certain proteins directly in the tumor tissue. Our test will help cancer patients (and their clinicians) to minimize undesired side effects and maximize their quality of life. Our first target will be breast cancer, but we will soon extend to several other types of tumors.